An interventional study of My Diabetes Care in Diabetes Mellitus, Type 2, sponsored by Vanderbilt University Medical Center. Completed at 2 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-20.
Sponsored by Vanderbilt University Medical Center · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Diabetes Mellitus, Type 2 by Vanderbilt University Medical Center — 4 open to participants now, 5 under way, none of them phase 3. Diabetes Mellitus, Type 2 · Vanderbilt University Medical Center.
Among the 21 studies in Diabetes Mellitus, Type 2 by Vanderbilt University Medical Center, this one is the 6th largest by enrollment of the 18 interventional ones that give a count, is the only one that started in 2023, is one of 13 with no phase, and was the 15th registered.
10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →4 of the 21 studies in Diabetes Mellitus, Type 2 by Vanderbilt University Medical Center are open now, in 1 country. Recruiting first, the newest first:
Vanderbilt University Medical Center · Sites in United States
Ages 18+
Vanderbilt University Medical Center · Sites in United States
Ages 21–65
Vanderbilt University Medical Center · Sites in United States
Ages 18–75
Vanderbilt University Medical Center · Sites in United States
Ages 65–85
By country, each count listing its studies:
Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 2 · Phase 3 1
First in 2007; this study’s year is marked. 1 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 458 is above the median of 80 across 8,372 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 135 across the 18 interventional studies, 172 across the 3 observational. Of the 15 that completed or were terminated, 12 (80%) have results posted.
This tab as a report to print or save as PDF → With an account.
Vanderbilt University Medical Center is the lead sponsor of 837 studies on the registry; 157 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 92 (73%) have results posted.
2 of the studies in Diabetes Mellitus, Type 2 by Vanderbilt University Medical Center that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06852950Vanderbilt University Medical CenterContinuous Glucose Monitoring for Outpatient Diabetes Management After Hospital Discharge | 2027-01 |
| NCT07210593Vanderbilt University Medical CenterSTrong Relationships to Improve DiabEtes Pilot | 2027-03 |
Add all 2 to your calendar (.ics) → With an account.
Among the 21 studies in Diabetes Mellitus, Type 2 by Vanderbilt University Medical Center, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to conduct a two-arm, parallel-design, pragmatic randomized controlled trial of a patient portal intervention for diabetes, My Diabetes Care (MDC), to evaluate its effect on clinical outcomes.
484 adult patients with type 2 diabetes mellitus will be randomized to one of two arms. 242 will be assigned to the intervention (My Diabetes Care) embedded within an existing patient web portal, My Health at Vanderbilt at Vanderbilt University Medical Center or Patient Gateway at Brigham and Women's Hospital. 242 will be assigned to a usual care comparison arm with access currently available version of My Health at Vanderbilt or Patient Gateway without the My Diabetes Care (MDC) application. Potentially eligible patients will be invited to be screened for enrollment in the study. Interested patients will be able to complete an electronic consent form and enroll online via Research Electronic Data Capture (REDCap). Outcomes data will be collected from patients at four time points: baseline (T0), three-month follow-up (T1), three-month follow-up (T2), six-month follow-up (T3), and twelve-month follow-up (T4). At each time point, study participants will complete questionnaires electronically via email using REDCap, participants' hemoglobin A1C level will be assess via home A1C test kits, and participants' diabetes health data will be abstracted from their electronic health record. Participants will be randomized to the intervention or control arm after their baseline data is collected.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients have access to an existing patient web portal (i.e., Epic's MyChart) embedded with My Diabetes Care.
Other: My Diabetes Care
Patients will have access to an existing patient web portal (i.e., Epic's MyChart) NOT embedded with My Diabetes Care (i.e., usual care)
My Diabetes Care (MDC) is a multi-faceted patient portal intervention for mobile devices that is designed to help patients better understand their diabetes health data as well as promote and support self-management. MDC uses infographics to facilitate patients' understanding of their diabetes health data (e.g., HbA1c, LDL) and provides literacy level-appropriate and tailored diabetes self-care information.
Also known as: Patient-facing Diabetes Dashboard
Change in Blood Glucose Control at 6 Months
Hemoglobin A1c will assessed using mail-in home HbA1c test kits and participants' most recent hemoglobin A1C will be abstracted from participants' electronic medical record.
Time frame: Baseline (T0) to Six-month Follow-Up (T2)
Change in Body Mass Index (BMI)
Participants' most recent body mass index (BMI) measurement will be abstracted from participants' electronic medical record.
Time frame: Baseline (T0), Three-month Follow-up (T1), Six-month Follow-Up (T2), Twelve-month Follow-up (T3)
Change in Low Density Lipoprotein (LDL)
Participants' most recent low density lipoprotein (LDL) measurement will be abstracted from participants' electronic medical record.
Time frame: Baseline (T0), Three-month Follow-up (T1), Six-month Follow-Up (T2), Twelve-month Follow-up (T3)
Urine Albumin-to-Creatinine Ratio
Participants' most albumin-to-creatinine ratio will be abstracted from participants' electronic medical record.
Time frame: Baseline (T0), Three-month Follow-up (T1), Six-month Follow-Up (T2), Twelve-month Follow-up (T3)
Change in Systolic Blood Pressure
Participants' most recent systolic blood pressure measurement will be abstracted from participants' electronic medical record.
Time frame: Baseline (T0), Three-month Follow-up (T1), Six-month Follow-Up (T2), Twelve-month Follow-up (T3)
Change in Diabetes Self-Care (General Diet Adherence)
The Summary of Diabetes Self-Care Activity (SDSCA) is a 10-item multidimensional instrument to assess levels of diabetes self-care across five domains: general diet (2 items), specific diet (2 items), exercise (2 items), foot care (2 items), and blood-glucose testing (2 items). The general diet subscale is used to assess general diet adherence. The instrument is based on the self-reported days completing recommended activities during the past 7 days. An example item includes "How many of the last SEVEN DAYS have you followed a healthful eating plan?" The general diet subscale score is the mean number of days for the 2 items in the subscale. The score range is from 0 days (worst) to 7 days (best).
Time frame: Baseline (T0), Three-month Follow-up (T1), Six-month Follow-Up (T2), Twelve-month Follow-up (T3)
Change in Diabetes Self-Care (Exercise Adherence)
The Summary of Diabetes Self-Care Activity (SDSCA) is a 10-item multidimensional instrument to assess levels of diabetes self-care across five domains: general diet (2 items), specific diet (2 items), exercise (2 items), foot care (2 items), and blood-glucose testing (2 items). The exercise subscale is used to assess exercise adherence. The instrument is based on the self-reported days completing recommended activities during the past 7 days. An example item includes "On how many of the last SEVEN DAYS did you participate in at least 30 minutes of physical activity?" The exercise subscale score is the mean number of days for the 2 items in the subscale. The score range is from 0 days (worst) to 7 days (best).
Time frame: Baseline (T0), Three-month Follow-up (T1), Six-month Follow-Up (T2), Twelve-month Follow-up (T3)
Change in Diabetes Self-Care (Diabetes Medication Adherence)
The Adherence to Refills and Medications Scale-Diabetes (ARMS-D) is a reliable and valid measure of diabetes medication adherence. The 11-item ARMS-D has good internal consistency reliability (α=0.86). Responses range from 1="none of the time" to 4="all of the time," and are summed to produce an overall adherence score ranging from 11-44, with higher scores representing more problems with medication adherence.
Time frame: Baseline (T0), Three-month Follow-up (T1), Six-month Follow-Up (T2), Twelve-month Follow-up (T3)
Change in Diabetes Self-Care (Self-Monitoring of Blood Glucose Adherence)
The Summary of Diabetes Self-Care Activity (SDSCA) is a 10-item multidimensional instrument to assess levels of diabetes self-care across five domains: general diet (2 items), specific diet (2 items), exercise (2 items), foot care (2 items), and blood-glucose testing (2 items). The blood-glucose testing subscale is used to assess self-monitoring of blood glucose adherence. The instrument is based on the self-reported days completing recommended activities during the past 7 days. An example item includes "On how many of the last SEVEN DAYS did you test your blood sugar?" The blood-glucose testing subscale is the mean number of days for the 2 items in the subscale. The score range is from 0 days (worst) to 7 days (best).
Time frame: Baseline (T0), Three-month Follow-up (T1), Six-month Follow-Up (T2), Twelve-month Follow-up (T3)
Usability of MyChart (for Control Group)
The usability of the patient portal (Epic's MyChart) will be assessed using the System Usability Scale (SUS). The SUS is a valid measure of usability and assesses users' perceptions of ease of use, likability of the interface, and overall satisfaction using a 5- point Likert scale (strongly disagree to strongly agree). The ten items are scored on a five-point Likert scale. The item scores are summed and then converted to a score ranging from 0 (worst) to 100 (best). Based on prior research, a score above 68 would be above average and a score of 85 or above suggests excellent usability.
Time frame: Twelve-month Follow-up (T3)
Satisfaction/Usability of My Diabetes Care (for Intervention Group)
The usability of the My Diabetes Care will be assessed using the System Usability Scale (SUS). The SUS is a valid measure of usability and assesses users' perceptions of ease of use, likability of the interface, and overall satisfaction using a 5- point Likert scale (strongly disagree to strongly agree). The ten items are scored on a five-point Likert scale. The item scores are summed and then converted to a score ranging from 0 (worst) to 100 (best). Based on prior research, a score above 68 would be above average and a score of 85 or above suggests excellent usability.
Time frame: Twelve-month Follow-up (T3)
Change in Diastolic Blood Pressure
Participants' most recent diastolic blood pressure measurement will be abstracted from participants' electronic medical record.
Time frame: Baseline (T0), Three-month Follow-up (T1), Six-month Follow-Up (T2), Twelve-month Follow-up (T3)
Change in Blood Glucose Control at 12 Months
Hemoglobin A1c will assessed using mail-in home HbA1c test kits and participants' most recent hemoglobin A1C will be abstracted from participants' electronic medical record.
Time frame: Baseline (T0) to Twelve-month Follow-Up (T3)
| Milestone | My Diabetes Care | Usual Care |
|---|---|---|
| Started | 221 | 220 |
| Completed | 216 | 214 |
| Not completed | 5 | 6 |
| Withdrew: Withdrawal by subject | 5 | 5 |
| Withdrew: Death | 0 | 1 |
Hemoglobin A1c will assessed using mail-in home HbA1c test kits and participants' most recent hemoglobin A1C will be abstracted from participants' electronic medical record.
| percentage of glycated hemoglobin | My Diabetes Care | Usual Care |
|---|---|---|
| Change in Blood Glucose Control at 6 Months | -0.6 ± 1.4 | -0.5 ± 1.4 |
Participants' most recent body mass index (BMI) measurement will be abstracted from participants' electronic medical record.
| kg/m² | My Diabetes Care | Usual Care |
|---|---|---|
| Baseline (T0) to 3-months (T1) | -0.5 ± 1.6 | -0.4 ± 1.6 |
| Baseline (T0) to 6-months (T2) | -0.8 ± 2.2 | -0.7 ± 2.0 |
| Baseline (T0) to 12-months (T3) | -1.3 ± 3.0 | -1.1 ± 3.3 |
Participants' most recent low density lipoprotein (LDL) measurement will be abstracted from participants' electronic medical record.
| mg/dL | My Diabetes Care | Usual Care |
|---|---|---|
| Baseline (T0) to 3-months (T1) | 11.0 ± 52.6 | 2.2 ± 33.1 |
| Baseline (T0) to 6-months (T2) | 5.5 ± 32.7 | -18.7 ± 33.0 |
| Baseline (T0) to 12-months (T3) | 2.5 ± 21.9 | -11.8 ± 26.1 |
Participants' most albumin-to-creatinine ratio will be abstracted from participants' electronic medical record.
| mcg/mg | My Diabetes Care | Usual Care |
|---|---|---|
| Baseline (T0) to 3-months (T1) | -14.2 ± 18.7 | — |
| Baseline (T0) to 6-months (T2) | 41.4 ± 123.1 | -225.9 ± 390.6 |
| Baseline (T0) to 12-months (T3) | -25.6 ± 84.2 | 83.5 ± 305.9 |
Participants' most recent systolic blood pressure measurement will be abstracted from participants' electronic medical record.
| mmHg | My Diabetes Care | Usual Care |
|---|---|---|
| Baseline (T0) to 3-months (T1) | -4.4 ± 19.8 | -3.1 ± 15.3 |
| Baseline (T0) to 6-months (T2) | -2.2 ± 18.8 | -1.1 ± 16.1 |
| Baseline (T0) to 12-months (T3) | 0.9 ± 18.4 | -4.0 ± 17.2 |
The Summary of Diabetes Self-Care Activity (SDSCA) is a 10-item multidimensional instrument to assess levels of diabetes self-care across five domains: general diet (2 items), specific diet (2 items), exercise (2 items), foot care (2 items), and blood-glucose testing (2 items). The general diet subscale is used to assess general diet adherence. The instrument is based on the self-reported days completing recommended activities during the past 7 days. An example item includes "How many of the last SEVEN DAYS have you followed a healthful eating plan?" The general diet subscale score is the mean number of days for the 2 items in the subscale. The score range is from 0 days (worst) to 7 days (best).
| score on a scale | My Diabetes Care | Usual Care |
|---|---|---|
| Baseline (T0) to 3-months (T1) | 0.2 ± 1.3 | 0.2 ± 1.3 |
| Baseline (T0) to 6-months (T2) | 0.3 ± 1.3 | 0.2 ± 1.3 |
| Baseline (T0) to 12-months (T3) | 0.4 ± 1.2 | 0.2 ± 1.3 |
The Summary of Diabetes Self-Care Activity (SDSCA) is a 10-item multidimensional instrument to assess levels of diabetes self-care across five domains: general diet (2 items), specific diet (2 items), exercise (2 items), foot care (2 items), and blood-glucose testing (2 items). The exercise subscale is used to assess exercise adherence. The instrument is based on the self-reported days completing recommended activities during the past 7 days. An example item includes "On how many of the last SEVEN DAYS did you participate in at least 30 minutes of physical activity?" The exercise subscale score is the mean number of days for the 2 items in the subscale. The score range is from 0 days (worst) to 7 days (best).
| score on a scale | My Diabetes Care | Usual Care |
|---|---|---|
| Baseline (T0) to 3-months (T1) | 0.2 ± 1.8 | 0.4 ± 1.7 |
| Baseline (T0) to 6-months (T2) | 0.3 ± 1.9 | 0.4 ± 2.0 |
| Baseline (T0) to 12-months (T3) | 0.4 ± 1.8 | 0.3 ± 1.9 |
The Adherence to Refills and Medications Scale-Diabetes (ARMS-D) is a reliable and valid measure of diabetes medication adherence. The 11-item ARMS-D has good internal consistency reliability (α=0.86). Responses range from 1="none of the time" to 4="all of the time," and are summed to produce an overall adherence score ranging from 11-44, with higher scores representing more problems with medication adherence.
| score on a scale | My Diabetes Care | Usual Care |
|---|---|---|
| Baseline (T0) to 3-months (T1) | -0.1 ± 3.1 | -0.3 ± 3.0 |
| Baseline (T0) to 6-months (T2) | -0.1 ± 3.6 | -0.2 ± 3.4 |
| Baseline (T0) to 12-months (T3) | 0 ± 3.3 | -0.2 ± 3.4 |
The Summary of Diabetes Self-Care Activity (SDSCA) is a 10-item multidimensional instrument to assess levels of diabetes self-care across five domains: general diet (2 items), specific diet (2 items), exercise (2 items), foot care (2 items), and blood-glucose testing (2 items). The blood-glucose testing subscale is used to assess self-monitoring of blood glucose adherence. The instrument is based on the self-reported days completing recommended activities during the past 7 days. An example item includes "On how many of the last SEVEN DAYS did you test your blood sugar?" The blood-glucose testing subscale is the mean number of days for the 2 items in the subscale. The score range is from 0 days (worst) to 7 days (best).
| score on a scale | My Diabetes Care | Usual Care |
|---|---|---|
| Baseline (T0) to 3-months (T1) | 0.1 ± 2.4 | 0.1 ± 2.3 |
| Baseline (T0) to 6-months (T2) | 0.3 ± 2.2 | 0 ± 2.4 |
| Baseline (T0) to 12-months (T3) | 0.2 ± 2.6 | 0.2 ± 2.6 |
The usability of the patient portal (Epic's MyChart) will be assessed using the System Usability Scale (SUS). The SUS is a valid measure of usability and assesses users' perceptions of ease of use, likability of the interface, and overall satisfaction using a 5- point Likert scale (strongly disagree to strongly agree). The ten items are scored on a five-point Likert scale. The item scores are summed and then converted to a score ranging from 0 (worst) to 100 (best). Based on prior research, a score above 68 would be above average and a score of 85 or above suggests excellent usability.
| score on a scale | My Diabetes Care | Usual Care |
|---|---|---|
| Usability of MyChart (for Control Group) | — | 79.3 ± 15.5 |
The usability of the My Diabetes Care will be assessed using the System Usability Scale (SUS). The SUS is a valid measure of usability and assesses users' perceptions of ease of use, likability of the interface, and overall satisfaction using a 5- point Likert scale (strongly disagree to strongly agree). The ten items are scored on a five-point Likert scale. The item scores are summed and then converted to a score ranging from 0 (worst) to 100 (best). Based on prior research, a score above 68 would be above average and a score of 85 or above suggests excellent usability.
| score on a scale | My Diabetes Care | Usual Care |
|---|---|---|
| Satisfaction/Usability of My Diabetes Care (for Intervention Group) | 75.0 ± 15.6 | — |
Participants' most recent diastolic blood pressure measurement will be abstracted from participants' electronic medical record.
| mmHg | My Diabetes Care | Usual Care |
|---|---|---|
| Baseline (T0) to 3-months (T1) | -1.3 ± 10.7 | -0.3 ± 10.6 |
| Baseline (T0) to 6-months (T2) | -2.2 ± 10.2 | -1.0 ± 12.0 |
| Baseline (T0) to 12-months (T3) | -1.8 ± 10.4 | -2.1 ± 10.3 |
Hemoglobin A1c will assessed using mail-in home HbA1c test kits and participants' most recent hemoglobin A1C will be abstracted from participants' electronic medical record.
| percentage of glycated hemoglobin | My Diabetes Care | Usual Care |
|---|---|---|
| Change in Blood Glucose Control at 12 Months | -0.5 ± 1.8 | -0.6 ± 1.6 |
Collected over 12 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| My Diabetes Care | 0/221 (0%) | 5/221 (2.3%) | 0/221 (0%) |
| Usual Care | 1/220 (0.5%) | 6/220 (2.7%) | 0/220 (0%) |
| Event | My Diabetes Care | Usual Care |
|---|---|---|
| HospitalizationInfections and infestations | 1/221 | 3/220 |
| HospitalizationGastrointestinal disorders | 2/221 | 0/220 |
| HospitalizationGeneral disorders | 1/221 | 1/220 |
| HospitalizationsMusculoskeletal and connective tissue disorders | 0/221 | 1/220 |
| DeathNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/221 | 1/220 |
| HospitalizationCardiac disorders | 1/221 | 0/220 |
| Age, Categorical(Participants) | My Diabetes Care | Usual Care | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 166 | 163 | 329 |
| >=65 years | 55 | 57 | 112 |
| Age, Continuous(years) | My Diabetes Care | Usual Care | Total |
|---|---|---|---|
| Mean | 56.3 ± 11.2 | 56.1 ± 11.1 | 56.2 ± 11.2 |
| Sex/Gender, Customized(Participants) | My Diabetes Care | Usual Care | Total |
|---|---|---|---|
| Female | 110 | 107 | 217 |
| Male | 109 | 113 | 222 |
| Other | 1 | 0 | 1 |
| Missing | 1 | 0 | 1 |
| Ethnicity (NIH/OMB)(Participants) | My Diabetes Care | Usual Care | Total |
|---|---|---|---|
| Hispanic or Latino | 9 | 19 | 28 |
| Not Hispanic or Latino | 211 | 200 | 411 |
| Unknown or Not Reported | 1 | 1 | 2 |
| Race (NIH/OMB)(Participants) | My Diabetes Care | Usual Care | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 |
| Asian | 13 | 7 | 20 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 38 | 42 | 80 |
| White | 153 | 158 | 311 |
| More than one race | 9 | 7 | 16 |
| Unknown or Not Reported | 7 | 6 | 13 |
| Region of Enrollment(participants) | My Diabetes Care | Usual Care | Total |
|---|---|---|---|
| United States | 221 | 220 | 441 |
| Language(s) Spoken(Participants) | My Diabetes Care | Usual Care | Total |
|---|---|---|---|
| English — Yes | 216 | 218 | 434 |
| English — No | 5 | 2 | 7 |
| Spanish — Yes | 12 | 9 | 21 |
| Spanish — No | 209 | 211 | 420 |
| Other — Yes | 6 | 7 | 13 |
| Other — No | 215 | 213 | 428 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — After study results are posted on clinical trials and published in a peer-reviewed journal, de-identified individual participant data that underlie the results reported will be available upon requests made to the principal investigator and ending after 36 months after publication.
Supporting information: Study protocol, Statistical analysis plan
Time frame: Deidentified individual participant data that underlie the results reported will be available after publication in a peer-reviewed journal and posted on clinical trials and ending after 36 months of publication.
Access criteria: Researchers should provide a methodologically sound proposal to achieve their proposed aims. Proposals may be submitted to the principal investigator up to 36 months following publication. To gain access, data requestors will need to sign a data access agreement.
Ran from Jul 2023 to primary completion in Jul 2025, 24 months.
Results were first posted in Nov 2026, 1 year 4 months after primary completion.
Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's 24 months is above that.
Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Vanderbilt University Medical Center →